183 related articles for article (PubMed ID: 27725113)
1. The increased antibody response to Epstein-Barr virus in multiple sclerosis is restricted to selected virus proteins.
Dooley MM; de Gannes SL; Fu KA; Lindsey JW
J Neuroimmunol; 2016 Oct; 299():147-151. PubMed ID: 27725113
[TBL] [Abstract][Full Text] [Related]
2. Antibodies to the Epstein-Barr virus proteins BFRF3 and BRRF2 cross-react with human proteins.
Lindsey JW
J Neuroimmunol; 2017 Sep; 310():131-134. PubMed ID: 28778437
[TBL] [Abstract][Full Text] [Related]
3. Epstein-Barr virus antibodies and vitamin D in prospective multiple sclerosis biobank samples.
Salzer J; Nyström M; Hallmans G; Stenlund H; Wadell G; Sundström P
Mult Scler; 2013 Oct; 19(12):1587-91. PubMed ID: 23549431
[TBL] [Abstract][Full Text] [Related]
4. Serologic Response to the Epstein-Barr Virus Peptidome and the Risk for Multiple Sclerosis.
Cortese M; Leng Y; Bjornevik K; Mitchell M; Healy BC; Mina MJ; Mancuso JD; Niebuhr DW; Munger KL; Elledge SJ; Ascherio A
JAMA Neurol; 2024 May; 81(5):515-524. PubMed ID: 38497939
[TBL] [Abstract][Full Text] [Related]
5. Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis.
Jilek S; Schluep M; Meylan P; Vingerhoets F; Guignard L; Monney A; Kleeberg J; Le Goff G; Pantaleo G; Du Pasquier RA
Brain; 2008 Jul; 131(Pt 7):1712-21. PubMed ID: 18550621
[TBL] [Abstract][Full Text] [Related]
6. Heightened Epstein-Barr virus immunity and potential cross-reactivities in multiple sclerosis.
Thomas OG; Haigh TA; Croom-Carter D; Leese A; Van Wijck Y; Douglas MR; Rickinson A; Brooks JM; Taylor GS
PLoS Pathog; 2024 Jun; 20(6):e1012177. PubMed ID: 38843296
[TBL] [Abstract][Full Text] [Related]
7. Untreated relapsing remitting multiple sclerosis patients show antibody production against latent Epstein Barr Virus (EBV) antigens mainly in the periphery and innate immune IL-8 responses preferentially in the CNS.
Sisay S; Lopez-Lozano L; Mickunas M; Quiroga-Fernández A; Palace J; Warnes G; Alvarez-Lafuente R; Dua P; Meier UC
J Neuroimmunol; 2017 May; 306():40-45. PubMed ID: 28385186
[TBL] [Abstract][Full Text] [Related]
8. Exploring the effect of vitamin D
Rolf L; Muris AH; Mathias A; Du Pasquier R; Koneczny I; Disanto G; Kuhle J; Ramagopalan S; Damoiseaux J; Smolders J; Hupperts R
Mult Scler; 2018 Sep; 24(10):1280-1287. PubMed ID: 28731372
[TBL] [Abstract][Full Text] [Related]
9. Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis.
Levin LI; Munger KL; Rubertone MV; Peck CA; Lennette ET; Spiegelman D; Ascherio A
JAMA; 2005 May; 293(20):2496-500. PubMed ID: 15914750
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for multiple sclerosis and associations with anti-EBV antibody titers.
Mouhieddine TH; Darwish H; Fawaz L; Yamout B; Tamim H; Khoury SJ
Clin Immunol; 2015 May; 158(1):59-66. PubMed ID: 25805657
[TBL] [Abstract][Full Text] [Related]
11. Combining HLA-DR risk alleles and anti-Epstein-Barr virus antibody profiles to stratify multiple sclerosis risk.
Strautins K; Tschochner M; James I; Choo L; Dunn DS; Pedrini M; Kermode A; Carroll W; Nolan D
Mult Scler; 2014 Mar; 20(3):286-94. PubMed ID: 23886832
[TBL] [Abstract][Full Text] [Related]
12. Multiple sclerosis and Epstein-Barr virus.
Levin LI; Munger KL; Rubertone MV; Peck CA; Lennette ET; Spiegelman D; Ascherio A
JAMA; 2003 Mar; 289(12):1533-6. PubMed ID: 12672770
[TBL] [Abstract][Full Text] [Related]
13. Association of serum Epstein-Barr nuclear antigen-1 antibodies and intrathecal immunoglobulin synthesis in early multiple sclerosis.
Pfuhl C; Oechtering J; Rasche L; Gieß RM; Behrens JR; Wakonig K; Freitag E; Pache FC; Otto C; Hofmann J; Eberspächer B; Bellmann-Strobl J; Paul F; Ruprecht K
J Neuroimmunol; 2015 Aug; 285():156-60. PubMed ID: 26198934
[TBL] [Abstract][Full Text] [Related]
14. No evidence for intrathecal IgG synthesis to Epstein Barr virus nuclear antigen-1 in multiple sclerosis.
Jafari N; van Nierop GP; Verjans GM; Osterhaus AD; Middeldorp JM; Hintzen RQ
J Clin Virol; 2010 Sep; 49(1):26-31. PubMed ID: 20638898
[TBL] [Abstract][Full Text] [Related]
15. Multiple sclerosis: the elevated antibody response to Epstein-Barr virus primarily targets, but is not confined to, the glycine-alanine repeat of Epstein-Barr nuclear antigen-1.
Ruprecht K; Wunderlich B; Gieß R; Meyer P; Loebel M; Lenz K; Hofmann J; Rosche B; Wengert O; Paul F; Reimer U; Scheibenbogen C
J Neuroimmunol; 2014 Jul; 272(1-2):56-61. PubMed ID: 24798244
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus-specific intrathecal oligoclonal IgG production in relapsing-remitting multiple sclerosis is limited to a subset of patients and is composed of low-affinity antibodies.
Castellazzi M; Contini C; Tamborino C; Fasolo F; Roversi G; Seraceni S; Rizzo R; Baldi E; Tola MR; Bellini T; Granieri E; Fainardi E
J Neuroinflammation; 2014 Nov; 11():188. PubMed ID: 25391491
[TBL] [Abstract][Full Text] [Related]
17. Higher EBV response is associated with more severe gray matter and lesion pathology in relapsing multiple sclerosis patients: A case-controlled magnetization transfer ratio study.
Jakimovski D; Ramanathan M; Weinstock-Guttman B; Bergsland N; Ramasamay DP; Carl E; Dwyer MG; Zivadinov R
Mult Scler; 2020 Mar; 26(3):322-332. PubMed ID: 30755085
[TBL] [Abstract][Full Text] [Related]
18. Teriflunomide's effect on humoral response to Epstein-Barr virus and development of cortical gray matter pathology in multiple sclerosis.
Zivadinov R; Ramanathan M; Hagemeier J; Bergsland N; Ramasamy DP; Durfee J; Kolb C; Weinstock-Guttman B
Mult Scler Relat Disord; 2019 Nov; 36():101388. PubMed ID: 31525628
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus-specific antibody response in cerebrospinal fluid and serum of patients with multiple sclerosis.
Castellazzi M; Tamborino C; Cani A; Negri E; Baldi E; Seraceni S; Tola MR; Granieri E; Contini C; Fainardi E
Mult Scler; 2010 Jul; 16(7):883-7. PubMed ID: 20483883
[TBL] [Abstract][Full Text] [Related]
20. The beneficial effects of vitamin D3 on reducing antibody titers against Epstein-Barr virus in multiple sclerosis patients.
Najafipoor A; Roghanian R; Zarkesh-Esfahani SH; Bouzari M; Etemadifar M
Cell Immunol; 2015 Mar; 294(1):9-12. PubMed ID: 25666504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
